Cargando…
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1
HIV-1 latent reservoirs harbouring silenced but replication-competent proviruses are a major obstacle against viral eradication in infected patients. The “shock and kill” strategy aims to reactivate latent provirus with latency reversing agents (LRAs) in the presence of antiretroviral drugs, necessi...
Autores principales: | Gohda, Jin, Suzuki, Kazuo, Liu, Kai, Xie, Xialin, Takeuchi, Hiroaki, Inoue, Jun-ichiro, Kawaguchi, Yasushi, Ishida, Takaomi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824842/ https://www.ncbi.nlm.nih.gov/pubmed/29476067 http://dx.doi.org/10.1038/s41598-018-21942-5 |
Ejemplares similares
-
BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells
por: Chen, Er, et al.
Publicado: (2020) -
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
por: Lin, C-C, et al.
Publicado: (2014) -
BI 2536 induces gasdermin E-dependent pyroptosis in ovarian cancer
por: Huo, Jianting, et al.
Publicado: (2022) -
BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells
por: Lian, Guodong, et al.
Publicado: (2018) -
Polo‑like kinase 1 selective inhibitor BI2536 (dihydropteridinone) disrupts centrosome homeostasis via ATM‑ERK cascade in adrenocortical carcinoma
por: Lin, Ruei-Ci, et al.
Publicado: (2023)